Clinical Trial Update: Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating a targeted CD19 or CD19-BCMA CAR-T therapy for autoimmune diseases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathies
• Sjogren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CD19 CAR-T therapy (targeted CD19/CD19-BCMA) (CD19-targeted CAR-T therapy)

Snippet

Sponsor: Nanjing Bioheng Biotech Co., Ltd. | Conditions: SLE (Systemic Lupus), Systemic Sclerosis | EARLY_Phase 1 | Status: RECRUITING